Celgene Corp (CELG) 147.40 $CELG
1 Biotech's Earnings the Market Got Completely Wrong
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun May 04, 2:03PM CDT
In this segment from Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass look at the recent earnings report from biotech company Celgene , to sift out the vital numbers that investors need to know. The guys...
Final Glance: Biotechnology companies
AP - Fri May 02, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Midday Glance: Biotechnology companies
AP - Fri May 02, 12:30PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri May 02, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Biotech Sector Performance in April: Gilead Sciences Rising
at The Street - Fri May 02, 8:49AM CDT
The biotech sector was down again, but there's some hopeful signs of a recovery.
New Drug Applications, Quarterly Results, and University Partnerships - Analyst Notes on Celgene, HCA, Thermo Fisher Scientific, Cubist and Agilent
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), HCA Holdings Inc. (NYSE: HCA), Thermo Fisher Scientific Inc. (NYSE: TMO), Cubist Pharmaceuticals Inc. (NASDAQ: CBST) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1941-100free.
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?
Up 50%: Merrimack Pharmaceuticals' Groundbreaking News
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu May 01, 5:30PM CDT
Shares in Merrimack Pharmaceuticals (NASDAQ: MACK) gained over 50% today on great news regarding a phase 3 trial for its MM-398 drug for pancreatic cancer. In combination with 5-flouroacil and leucovorin, MM-398 generated a 1.9 month lift in...
Critical Alerts For Coca Cola, Baidu.com, Urban Outfitters, Celgene, and Trina Solar Released By InvestorsObserver
PR Newswire - Thu May 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for KO, BIDU, URBN, CELG, and TSL.
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Earnings Roundup: Celgene's Rock-Solid Quarter Offers Opportunity
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Celgene is one of the most prolific deal makers in the biotech industry, inking dozens of collaborations with emerging biotechs working on the next big thing in medicine. Celgene's collaborations aim to expand upon an already-impressive...
After Yesterday's Rally of 2.75% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Apr 29, 3:45PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $142.10 to a high of $148.00. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $144.95 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Celgene Rises 2.75% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Apr 29, 3:45PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $142.10 to a high of $148.00. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $144.95 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
1 Biotech's Earnings the Market Got Completely Wrong
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun May 04, 2:03PM CDT
In this segment from Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass look at the recent earnings report from biotech company Celgene , to sift out the vital numbers that investors need to know. The guys...
Final Glance: Biotechnology companies
AP - Fri May 02, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Midday Glance: Biotechnology companies
AP - Fri May 02, 12:30PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri May 02, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Biotech Sector Performance in April: Gilead Sciences Rising
at The Street - Fri May 02, 8:49AM CDT
The biotech sector was down again, but there's some hopeful signs of a recovery.
New Drug Applications, Quarterly Results, and University Partnerships - Analyst Notes on Celgene, HCA, Thermo Fisher Scientific, Cubist and Agilent
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), HCA Holdings Inc. (NYSE: HCA), Thermo Fisher Scientific Inc. (NYSE: TMO), Cubist Pharmaceuticals Inc. (NASDAQ: CBST) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1941-100free.
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?
Up 50%: Merrimack Pharmaceuticals' Groundbreaking News
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu May 01, 5:30PM CDT
Shares in Merrimack Pharmaceuticals (NASDAQ: MACK) gained over 50% today on great news regarding a phase 3 trial for its MM-398 drug for pancreatic cancer. In combination with 5-flouroacil and leucovorin, MM-398 generated a 1.9 month lift in...
Critical Alerts For Coca Cola, Baidu.com, Urban Outfitters, Celgene, and Trina Solar Released By InvestorsObserver
PR Newswire - Thu May 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for KO, BIDU, URBN, CELG, and TSL.
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Earnings Roundup: Celgene's Rock-Solid Quarter Offers Opportunity
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Celgene is one of the most prolific deal makers in the biotech industry, inking dozens of collaborations with emerging biotechs working on the next big thing in medicine. Celgene's collaborations aim to expand upon an already-impressive...
After Yesterday's Rally of 2.75% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Apr 29, 3:45PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $142.10 to a high of $148.00. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $144.95 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Celgene Rises 2.75% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Apr 29, 3:45PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $142.10 to a high of $148.00. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $144.95 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
